Takuva, Simbarashe G.Nabyoma, J.M.Dawood, H.Black, A.Maartens, G.Parrish, AndrewLeong, T.D.2020-06-022020-06-022019-04Takuva, S., Nabyoma, J.M., Dawood, H. et al. 2019,'Eligibility for co-trimoxazole prophylaxis among adult HIV-infected patients in South Africa', South African Medical Journal, vol. 109, no. 4, pp. 198-199.2078-5135 (online)0256-9574 (print)10.7196/SAMJ.2019.v109i4.13877http://hdl.handle.net/2263/74823Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) is a broad-spectrum antibiotic used to prevent opportunistic infections in patients with HIV infection. Primary prophylaxis with co-trimoxazole has been shown to decrease hospitalisation, morbidity and mortality among people living with HIV, primarily by decreasing rates of malaria, pneumonia, diarrhoea, Pneumocystis pneumonia, toxoplasmosis and severe bacterial infections.Co-trimoxazole is inexpensive and widely available. In standard adult treatment guidelines and essential medicine lists in South Africa (SA), the current recommendation is that co-trimoxazole should be provided for HIV-infected patients with a CD4+ count ˂200 cells/µL, HIV/tuberculosis (TB) co-infection and/or advanced HIV disease (World Health Organization (WHO) stage 3 or 4).en© 2019, South African Medical Association. This article is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0).AIDS-related opportunistic infectionsCD4 Lymphocyte countHuman immunodeficiency virus (HIV)Drug combinationAdultSouth Africa (SA)Article